English
Home > Products > 186826-86-8

China 186826-86-8 Factory

We rely upon strategic thinking, constant modernisation in all segments, technological advances and of course upon our employees that directly participate within our success for 186826-86-8,CAS NO 186826-86-8,Moxifloxacin API,Moxifloxacin hydrochloride, For additional information and facts, please speak to us as quickly as possible!
186826-86-8, We always adhere to follow the honesty, mutual benefit, common development, after years of development and the tireless efforts of all staff, now has perfect export system, diversified logistics solutions, extensive meet customer shipping, air transport, international express and logistics services. Elaborate one-stop sourcing platform for our customers!

Related Products

Hot Products

  • 3-AMINO-1,2,4-TRIAZINE

    3-AMINO-1,2,4-TRIAZINE

    Product Name:3-AMINO-1,2,4-TRIAZINE
    Molecular Formula:C3H4N4
    Molecular Weight:96.09
    CAS Registry Number:1120-99-6
  • Stepronin

    Stepronin

    Product Name:Stepronin
    Molecular Formula:C10H11NO4S2
    Molecular Weight;273.33
    CAS Registry Number;72324-18-6
  • (S)-2,4-dichloro-a-(chloromethyl)-benzenemethanol

    (S)-2,4-dichloro-a-(chloromethyl)-benzenemethanol

    Product Name:(S)-2,4-dichloro-a-(chloromethyl)-benzenemethanol
    Molecular Formula:C9H9Cl3O3S
    Molecular Weight:303.59
    CAS Registry Number:229334-55-8
  • Lafutidine

    Lafutidine

    Product Name:Lafutidine
    Molecular Formula:C22H29N3O4S
    Molecular Weight;431.55
    CAS Registry Number;118288-08-7
  • Naproxen sodium

    Naproxen sodium

    Product Name:Naproxen sodium
    Molecular Formula:C14H13O3.Na
    Molecular Weight;252.24
    CAS Registry Number;26159-34-2
  • Phloroglucinol

    Phloroglucinol

    Product Name:Phloroglucinol
    Molecular Formula:C6H6O3
    Molecular Weight;126.11
    CAS Registry Number;108-73-6
  • Related Blog
  • Reviews

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

Related Search

CAS NO 186826-86-8

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept